<SEC-DOCUMENT>0001193125-26-237882.txt : 20260526
<SEC-HEADER>0001193125-26-237882.hdr.sgml : 20260526
<ACCEPTANCE-DATETIME>20260526073306
ACCESSION NUMBER:		0001193125-26-237882
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260526
FILED AS OF DATE:		20260526
DATE AS OF CHANGE:		20260526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Virax Biolabs Group Ltd
		CENTRAL INDEX KEY:			0001885827
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41440
		FILM NUMBER:		261015943

	BUSINESS ADDRESS:	
		STREET 1:		BIOCITY GLASGOW
		STREET 2:		BO'NESS ROAD, NEWHOUSE
		CITY:			LANARKSHIRE
		STATE:			X0
		ZIP:			ML1 5UH
		BUSINESS PHONE:		44 020 7788 7414

	MAIL ADDRESS:	
		STREET 1:		BIOCITY GLASGOW
		STREET 2:		BO'NESS ROAD, NEWHOUSE
		CITY:			LANARKSHIRE
		STATE:			X0
		ZIP:			ML1 5UH

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Virax Biolabs (Cayman) Ltd
		DATE OF NAME CHANGE:	20210930
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>6-k_5.26.26_data_webinar.htm
<DESCRIPTION>6-K
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-26T07:21:47.3915+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>6-K</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM 6-K</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF FOREIGN PRIVATE ISSUER<br>PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the month of May 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: 001-41440</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Virax Biolabs Group Limited</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#x2019;s Name)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BioCity Glasgow</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bo'Ness Road Newhouse</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lanarkshire, ML1 SUH</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 20-F </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     Form 40-F </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When used in this Form 6-K, unless otherwise indicated, the terms &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Virax</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; refer to Virax Biolabs Group Limited. and its subsidiaries.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Contained in this Form 6-K Report</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 26, 2026, Virax Biolabs Group Limited issued a press release today reporting positive early pilot performance data for ViraxImmune&#153;, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (&#x201c;ME/CFS&#x201d;) and related post-acute infection syndromes (&#x201c;PAIS&#x201d;). In the pilot dataset, ViraxImmune&#153; demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value (&#x201c;PPV&#x201d;) &#x2014; early performance metrics that Virax believes support continued development and advancement into larger clinical validation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on estimates derived from CDC, the RECOVER Initiative and other peer-reviewed and public-health sources, Virax estimates that up to 21 million adults in the United States may currently be living with Long COVID and related PAIS conditions, with approximately 2.5 million new cases estimated each year. Virax believes this represents a significant potential U.S. testing opportunity in an area where many patients are often assessed through symptoms and exclusion, rather than objective immune biomarkers of the type ViraxImmune&#153; is being developed to assess.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highlights:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the pilot dataset, ViraxImmune&#153; demonstrated measurable separation between PAIS patients and healthy controls and achieved 88% specificity and 92% positive predictive value (&#x201c;PPV&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ViraxImmune&#153; has now been evaluated in more than 120 subjects in the Company&#x2019;s ongoing UK clinical study in Long COVID, ME/CFS and related post-acute infection syndromes.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Findings support continued advancement toward Virax&#x2019;s intended U.S. market-entry strategy: an initial PAIS-focused U.S. Laboratory Developed Test (&#x201c;LDT&#x201d;) route, with broader in vitro diagnostic (&#x201c;IVD&#x201d;) development planned over time.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the press release dated May 26, 2026 is included as Exhibit 99.1 to this report.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:1.06%;box-sizing:content-box;"></td>
     <td style="width:88.94%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit No</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vrax-ex99_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">99.1</font></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vrax-ex99_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press release dated May 26, 2026</font></a></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"></td>
     <td style="width:44%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VIRAX BIOLABS GROUP LIMITED</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James Foster</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Foster, Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vrax-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-26T07:21:47.3906+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><img src="img90071954_0.jpg" alt="img90071954_0.jpg" style="width:400px;height:60px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune&#153; in Long COVID and Related Post-Acute Infection Syndromes</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:18pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LONDON, May 26, 2026 /PRNewswire/ - </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax Biolabs Group Limited (NASDAQ: VRAX) (&#x201c;Virax&#x201d; or the &#x201c;Company&#x201d;) today reported positive early pilot performance data for ViraxImmune&#153;, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (&#x201c;ME/CFS&#x201d;) and related post-acute infection syndromes (&#x201c;PAIS&#x201d;). In the pilot dataset, ViraxImmune&#153; demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value (&#x201c;PPV&#x201d;) &#x2014; early performance metrics that Virax believes support continued development and advancement into larger clinical validation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Based on estimates derived from CDC, the RECOVER Initiative and other peer-reviewed and public-health sources, Virax estimates that up to 21 million adults in the United States may currently be living with Long COVID and related PAIS conditions, with approximately 2.5 million new cases estimated each year. Virax believes this represents a significant potential U.S. testing opportunity in an area where many patients are often assessed through symptoms and exclusion, rather than objective immune biomarkers of the type ViraxImmune&#153; is being developed to assess.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Highlights:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In the pilot dataset, ViraxImmune&#153; demonstrated measurable separation between PAIS patients and healthy controls and achieved 88% specificity and 92% positive predictive value (&#x201c;PPV&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ViraxImmune&#153; has now been evaluated in more than 120 subjects in the Company&#x2019;s ongoing UK clinical study in Long COVID, ME/CFS and related post-acute infection syndromes.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Findings support continued advancement toward Virax&#x2019;s intended U.S. market-entry strategy: an initial PAIS-focused U.S. Laboratory Developed Test (&#x201c;LDT&#x201d;) route, with broader in vitro diagnostic (&#x201c;IVD&#x201d;) development planned over time.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">If validated in larger studies, ViraxImmune&#153; could become one of the first objective immune-profiling approaches developed specifically for Long COVID, ME/CFS and related post-acute infection syndromes. Virax believes this approach could support a differentiated diagnostic strategy in an area of significant unmet need, with potential applications in patient stratification, clinical decision-making</font><font style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> longitudinal monitoring and therapeutic development.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;These early pilot data mark an important step in the development of ViraxImmune&#153; as a potential objective immune-profiling test for Long COVID, ME/CFS and related post-acute infection syndromes,&#x201d; said James Foster, Chairman and Chief Executive Officer of Virax Biolabs. &#x201c;The observed separation between patients and healthy controls, together with encouraging early performance metrics, supports our confidence that ViraxImmune&#153; has the potential to address a major unmet diagnostic need as we advance toward our planned U.S. LDT-first route to market.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Patients with Long COVID, ME/CFS and related post-acute infection syndromes often face lengthy diagnostic journeys and limited objective testing options,&#x201d; said Dr. Sean Knight, MD, PhD, Principal Investigator at the Lydia Becker Institute of Immunology and Inflammation, University of Manchester, and Consultant Respiratory Physician at Northern Care Alliance NHS Foundation Trust. &#x201c;Objective immune profiling may help improve how these patients are assessed, stratified and monitored over time. These early pilot findings are encouraging and support further clinical validation of ViraxImmune&#153;.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax will host an investor webcast on May 26, 2026, at 4:15 p.m. ET to review the early ViraxImmune&#153; dataset, discuss the clinical and commercial implications of the findings, and outline the Company&#x2019;s planned path toward larger clinical validation, assay finalization and U.S. market entry. Interested parties may register for the webcast at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">this link</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. A replay will be made available following the event.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ViraxImmune&#153; is in development and is not approved for diagnostic use in any jurisdiction. The VRX003 observations are preliminary and are intended to inform ongoing assay development and future clinical validation planning.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Virax Biolabs Group Limited</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is developing T cell-based test technologies intended to support an immunology profiling platform. T cell testing may have applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.viraxbiolabs.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Caution Concerning Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as &#x201c;may,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;estimates,&#x201d; &#x201c;believes,&#x201d; &#x201c;plans,&#x201d; &#x201c;projected,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; or &#x201c;hopes&#x201d; or the negative of these or similar terms.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of preliminary, interim or top-line data to accurately reflect the complete results of a trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA and other regulators&#x2019; agreement on the regulatory path for ViraxImmune&#153; or other potential products; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the &#x201c;Risk Factors&#x201d; section of Virax&#x2019;s Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virax Biolabs Group Limited<br>Phone: +44 020 7788 7414<br>Email: info@viraxbiolabs.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dave Gentry, CEO<br>RedChip Companies, Inc.<br>Phone: 1-407-644-4256<br>Email: VRAX@redchip.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img90071954_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img90071954_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ 9 # 2(  A$! Q$!_\0
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M%^GZ/I=W%KMOHD4=K_9$VH7$;6S:7IMHP$G]H2HZR;\A0?E(Q7T//D_]D?\
M4S].EU=V3W^=K6/P#ZGXL?\ $55BOK+7 .O_  G_ .Q]<&G?3_;/]\;>^]UZ
M?=_E^_Z?_7H\OW_3_P"O2><GO^5*TL:]6'^?K7SQ^]<]/LO_ "7_ #)**IK.
MC?<=/PDS^9Z4[[9#_?7\S_A1;^OZ]1>WI_S%JD) ZFJ NXAUDC_\=_F3_GKF
MKBR*X_SC\_\ Z_XFFU;M\FA0Q%*IHFGVV??MMV#R_?\ 3_Z]'E^_Z?\ UZ=O
M7U_0_P"%,\Z%?XT'XBD5ST^R_P#)?\R6BF[E/?\ I_.F-+L^\,?Y_'^=!J2T
M5&C[\_Y_J?:I* *]2+A% /X#\O\ ]9I(NK_4?R%9-Y),+6=; QB\:.<6\DL1
MFMQ<X'_'T+,#N1D9!QZL-I5))I)^?YLYZE3V=*_>_P"?ZWL?)W[5_P"U=X-_
M9D\%S:AJ$L&K^.=6@EA\&>"X+@1W>K7#8'VJZSG[+I%B3Y]]?3+L6,)9627-
M]=6MG=?S\_#?]MKXW^"/C9?_ !IU'7YO%$_B:\BC\;^$+AC%HFLZ! TYM-$T
MJ',[Z0=!CNYCX;OK47-U9W,MS<:BVM1ZCKUK><9^UEI'QPTCXW>*1^T%)+>>
M,KJ8O;ZK$DO_  C=]X?\V8Z7-X)\YYI(O#.YYOL=JSF[L[QKZ+6POB9-76OF
MROUG(\@P5/ J5;_;/KB2=M;VM=+39.[[*_D?Y>>,OC=Q=CN.$L&\?DN$X8S%
M?V;EO_,=]?M_ON.7IVNK.R7;^QOX)?&?P)\<_ VB^.O &J+>6&I0(;NP9T&J
M:)J)1#=Z)KMH'E:UO;1G"LI9X;J![>\L;B\L;JTO+KVX&48)Z%>A(SNSV'7O
MUY'MT-?S.?\ !,K2?CS<?&E-0^&3BT^'=M/%'\6[K65N)/#=WHX226#3H((S
M'+<^-=C&?2;BSDC71VF6YUBX?3+F;2-=_IC5CM8<%P,@?7_(SVS7Y_GF7T\!
MC?JM+$<WI[STY7J^FKW;6EG?37^[O!KCK'<?\(8?-\QR9Y+B8_[!9/\ V#,$
MFO\ ;L#LG%[>K]2_1117CGZZ?CM_P49_:Q^,_P"S[XP^'N@_#+7=)T6R\2:%
MK^H:G)>:)8ZW>FXL-0TN"U,#7T-Q';HMO>SYVQL68JQ8B'#7_P#@FC^T=\9O
MC[J_Q@D^+/C"7Q5'X=3P*^AP?V-X>TBVTQ=6'BP7XA30-+TP3?:CIMHS&Z$[
M(8'$+A6E4_-7_!8/_DI7P<(QSX4\5DXZY_MOP_G/X ?A[5U7_!&XH-2^/1?J
M+?X99]_WOCS(X]L^^/:ON?JF%_U:^M_5V\5WT6FBWU2>MU9[_(_AO#\7\2U/
MI+8CAVMG68/(%F+_ .$[Z^UE_P#N2QC_ -A\K6?77NTS]Y:*I?:[?_GI%3TG
MBDY1OKAL?GQBOA[-]OO7^?G_ %8_M[V]/^8\3^/GQ57X)_"3QC\4UT5O$*^#
MM)CU0Z(EZ]A)?"6^M;)8%O$L=1^SY>Z!\PVDH0 L8Y"%C/YA_#[_ (*L:U\2
M/BA\// -A\%+70K;QCXS\.^%[S4[KQRVI2V,6MZU:::;J"QA\-:9]J:."ZWM
M&T\(\Q-N\]&_43XV_"NQ^-7PL\8?"_4=6OM%T[Q;I*Z7/J>FI;27UG''>6M\
MEQ:"\AN+;S1);(/WUO.H4MN1L@#\_/AS_P $K?A]\.O'?@WX@V7Q5\=:E?>#
M?%6B>*+2RU&#PR]A=7.BZG;:C%:W<=OH]O(]J\EJ%=$EAE9&8&4X"K[V6U,K
M6&Q#Q:OBKKE5M?AC]VO;I?KM^'>(6'\4ZO%7#O\ J;B5@\@_V#_6.WU/7_;5
M]=_WW6_U/?6S?GJ?K8C.1EU(/MU_+_#IBI:BBZO]1_(4K2H@^9A_GOZ5X!^Y
M_P#+O^OY@#^OY_\ UJ0E23QGWR1_GM_GK3%]#WD3_OX,_H:M*T;C(XXX.2?I
M_G&.*JS3T>MNC[F4:^'JI6:^=NR[?J?)7[:7Q2\6?!K]G?QU\2/ ]S96OB7P
M_-X4CT]M0M!J5HXU7QAH&D7BO;,K"<_8+^Y9"05214DD#1JZM^0/[-'[<W[3
MOQ4_:*^$W@WQ?\0[2?POXB\4S:?JVD6?A7PGID5U!#H>LWZP_;K31[?5.)K2
M#/\ IP!"D%"&.[]-?^"D*$?L>_% CB3S/ P(!R,#XB^$<$$G@Y)_NG'7T7\%
M?V*,G]JWX( ''_%8W_)SP/\ A%]=Y&>,8QC'&/PK[KA_+\+6R?'5JV'C+%+Z
M[RNW,M,&FG?O'>ZVM?1H_B[QHXQXARCQFX*R7+LZS'!95C5@/[1RW 8YK X^
M^.7Q)ZKS2>EE>^I_7:20@(ZX']*522 3_GFJL4@6,#_]>?\ ((_K2M<KV9/?
M#@_S'\J^$MJEW^>^VUS^T?;4^3K9I>EV]'?UU_ <GR=/Q]ZDW_+_ +7T_7_/
M?MBJJ7=N_&^/\).W;!S]>X_G4H.1FD:PJTJFM.VRO;7^G\S\\/\ @H7\>/B5
M^S_\*/#/BWX9WVDZ;K.K>/=.\/7L^K:5::G#'IM[X<\57KM!;7L<L?VB.]TV
MR*.\,L:Q^<Q4MM<?#/[$'[9'[1'QF_:5\->$?B)X]75O"U_HGB>XN= M/#7A
M72K-YM.TB:]LYC/8:1!J>ZVN8D(1+Y4>,NDL4D>*^A_^"O<>?@5X&D)Z?%C2
M/E'I_P (3X]YZ^GJ/<=,'\X?^"8YQ^USX-R,K_PC?B_=C.?^1=EP3]#R/QV_
MQ5]YE>"PE3A[$8OZNOK*6-U>_NJ+N[[VW37=V[G\2\=\7\2X7Z0?#G#V%SK,
M<)D/]H9??+UCK8!_7[7_ -BMO\NKT/ZD"H&,M^G_ .NDRO\ =_4U&+E>[)_W
MU]/0'_\ 7[<4Y)8G^[@XXX)_KCW]?2OA'2\K^=W^K/[6CB:,K)2M?6UK?D6*
M**C>5$^\<4CH';U]?T/^%&]?7]#_ (53^U6_]^/_ +[/M_\ 7_3WIXN%/\*_
MEC^?X_IZT6.;VV'_ )E]_P#P3^23Q[^T'^UA\/\ QKXK\#:K\=_BA'?^$=?U
MCP_>2MXFOU\R72+Z6R-VFVX=C%>&%KF*4NSNDPEDQ*S;/Z,_V-_B[+\9_P!G
M?X=>-K[4%U'7ET1=#\5R";S)6\3^')I-#UB:Y#!?*FO[ZPEOTC10B6]S"%VJ
M0@_%K_@J?\)!X*^.>E_$*PM'ATGXI: D]S)%"ZQ_\)#X4CLM'U-3*H: 37&C
M-X;F16*2S7+W3KY@1A#]$_\ !('XI%[7XH_!R_N6;[%<V7C[1(I3&X^R7D5E
MX?U^..,!94AMKFTT&Y7>9 UQJTY1]JE(_N\UPV%QV28;'T<,DTTW977V;W\]
M'UT;6MKH_A;PFS_B'@KQGSG@?B+.LPQV&QOU[+\M_M''8W'/IC<#CKXS_J#5
MFO/571]N?\% _C%J?P9_9S\3:OX=UVYT/Q;XFOM,\(^%+ZPFAM+^WU/5;CSK
MK4+"619,7FFZ%9ZUJEN51V$VGH-I)1&_&/\ 93^-?[4'Q4_:&^%W@Y/C3\1]
M2T^Z\5:;J_B&QO?$&H7=A/X8\/.=<\0:?>V\UP8_L>K:9ITVE,N#E[P+D9>1
M?;_^"M?Q336OB/X$^$^FR%K'P3H=WXFUJ-!\KZ[XKD6TTF.:4D[9](TC3;BY
MB"(6^S^(QNPK_O>[_P""0?PD9KWXD_&W4;0%(Q;^!O#$TL8#'<MCK?BN="9#
ME/\ D7+>TE2)"ICU*-]ZF(L8/#87 </5\56PZ>*QFD6ULVTM':VNBNMUI?9G
M1Q/G^>\=>/\ EW#&1YUF."RG)'@?[2_L_'8R*?U'_;,<M-'M:V[;MHSN/^"G
MGQ_^,?PA\7?#+1/AEX]U7PCIOB#PWXKN=9ATFWT5Y;F>PU#0;>SE6?4;"]N8
MF\B^O%80^5&?D)9Y$!6A_P $MOC+\6/BCX[^+J?$CXC>*?&D>EZ#X4ETJT\0
M:OJ&HVUK+J&H>(/M\UG;3N]M:^8MG91,8@C.BJ BA7#>6?\ !8?;_P +'^#7
M  _X17QCG'?_ (G/ASGCCIZ?X59_X(ZX_P"$\^-?7CPWX)Y[ _VSXN )[<9/
MX8[YK3ZOA'PI[?ZO?%<M^:R;M]:CKVV^ZWG9YT\_SU?2:_L19UF*RK^T/^1;
M]?QGU!)8&+M]2ORWOTOI\SR7]N+]I[]H/P[^T3\4/ 'AKXN^,= \(Z#J.C6F
MDZ3X;O+?1)+:*^\*:!J-XPU+3;:VUAF.H75V%#ZBT:J5*+&50)X!\0_VT?VD
M?BI8>&_":>.O$6CZ5H^@Z?I7]G>#-1O]+U7Q+>VEA8VM[KGB;7;*6+6-4U74
MIK62YNK;[5;Z'YD\CKID<ZO<R6?V^@$_:Y^,D0)8#5?#P5@.H'@;PP=Q]_3U
M)+<?=K]8O^"4_P /?!-M\"I/B!%X;TQO&6I^*?$VE7OB&>T@DU=[#39[:"WT
M^&_E7S;>Q!S-]FMRL$\Q>]D5C/ T?;5J8+*\HR[,7EZ?FW9.6BN]-+]E=I=M
MC\\RNAQQXB>+'%?">$XLS')LI_M#'_VC?'8W&K^S\#C4G@<!?%Z)I[+HW>]D
M?-G[!&H_%3X:_#W]K'XH^,$\>:=>>$_ %KJ?AP>/(O$7V?\ M*QTCQKK5_=V
M=IXHYO#]NL])_M=N.0 3SBOAB;XW_MD?'.\)LO&WQH\:SSMBZT_P$FO6FF9D
M:1P[Z-X'M;#3[5!L8>8EK!$<?,VXDO\ U=ZOX>T+Q!H]]X>U[3-.UK1M6MS;
MZCI>JV5O?6%_ PP]O=VES'+#<0/\RR1R*T9&59'#%*\Z\0?$_P""'PDCM]%\
M1^-OAUX%AMK=FM]'U'7O#WA[RH -P%IID][:'R@3A!!:F,<JF"N1\_0SRF\3
MB,7_ &<I8K&:]FEI=[:-:OYVVLC^BLZ\%<3+(\DR2IXB9CDV59,L<\Q:_P"9
MCCL?C4V\<WBUI9+7N^UC^5WQ+X6_:B^&4/\ PE'BVP^.G@NW\ZVC'B/6Y/'F
MB(9X]S6B'6IKBWFF*[G\N%KIR!T0*N4^M/V2_P#@H1\7? 7CCP[X3^*?BZ]\
M;_##6M3BTG4+SQ)F]\1^&C>S);VVN0>(3G4[ZPL;C9)J=GJG]L3#38YH='CM
M;J.*UNOUZ^)?[4'[)7C3P)XR\+ZG\9?A1K5CKGAK7M,GTYO&&A3_ &F*[TRY
MCFM]HOFRQA,JA1\Y&-GS;#7\I_SI:_?_ 'D=K^GV3]1_CCWKZ3 3HYSAJ]',
M<N^IM6Z?X==?17_I'\V<;T\3X,\3<.8KA/CS,,YPF,UM]?3_ -QM_L&/M_L?
MU/&>EU<_M&^)?AW6/&'P\\9>'O#GB*^\,Z_KOAK6-.T7Q-ID\UG?Z'JEY8S6
MNFZM:7-J\=Q'/IEZ\-[#L9,M %RH+-7\K_BOXV?M;?"SQQK'A3Q-\8OBQIOB
M[P9KH34=.O\ QOXDU#36OK6=;M%>TN]1GT_5=%U)&@NDC>&ZTK5K"X@F\N[L
M;F,R_P!5W@"X:X\&>%YYR7GG\.Z-+)*2</*=-MFD8=.K%B./J!D5^9__  4K
M_9(7XF^$3\</ .EP'QSX&TV1_$NGVD6;GQ;X/LUFN[E2T6R2?6= <R7MB=LD
M]WIIU&Q"7MZNB6MM\MP_B\+A<7]5Q6'OAL4TKV5T_=O>VVC?K=V\OZ?\=>%^
M(.(>%</Q7PQF68X+-,FR]9A_9V7X[&6S# ;O9K7K;R3W6GV)^RG^T+HO[1_P
MAT3QS UI:^(K9(]+\:Z1!.KMHGB>TMX7OH""0Z6MV)8M0TY)1YWV"[MQ<E;L
M7$47XN?MQ_MN^//&GQ=O?#'PA\?>*/!W@7P$\_AZ/4?"&N7.C?\ "6Z\\L)U
M75)KW0=10W^EV5Q;II^B!S)%B&]U.SF>VUB!;;X=^%/Q[^(?P<L?'&F_#_Q!
M)IME\0?#<WA_6E0N%6/S(WM-;T\Q-%-:ZUIEM<7MO87T<BR6=KJ>H>1LNKB*
MYA]K_8F_9@N_VD_BC'::G;7,'PZ\&G3]6\<:E"A$5TC2ROI?AF"Z93FZUUK*
M6*=XF1[*QAN[P7$-[]D@N_H</D&"RS$XG,,9KA;Z7O?HM&M];JUD^W8_GC,/
M&?B_Q3R?A/@/AC^T<'Q!C;?ZQYEK@/K_ -1MHK.S6V*Q=ODM+O\ 7_\ X)I:
M!\<[_P"'FN?%/XQ_$#QOXKT_Q]_9?_" :/XP\0:MK<MEX;TR.[:7Q,$U2XF>
MU/BBYOE6UM_FCFTS1M.U:UGN+/6HG7]/5\S=(1CR]I\M0!SD<DG.>...^?2L
MS2=.M-'L+/2["""TL;&W@L[6VAC$4-M;VL:P6UO#"@54@BC1$18QMC1%4
M5XE^TI\89O@-\)O%7Q+@\+ZKXRET&SWIH^D0/($DG_<?;]2F7>;/2-/#-<ZO
M?[)?L6G6]S>&WG\@QM\-.?U_'6HX=7Q=K66B2<7%6;WU4=6M.RV_N;(,OI<
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MIO[&G[8_BK]FGQ4MC>RWWB'X6:[>0KXE\*V["6\T668>0?$OA>"61(HM5AC
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MNJ6-]:))=);?:IOJ/[0P.>?7\J?=2CKNTUJOGUZ/0_F6EP/QIX)/ASQ(5_\
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M3'=+;;_I<*D4N[;$62627_GEQC_]>>G\Z39(WR(A\SO^Z^G_ -;Z>GK^^/[
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M^/7B=DWBMEF2\)\&+,<YQ7]H+,7_ +#C5K_N7U':[TQ?R[KI^BW@O2[S3?\
M@DO\4;NY7RX]=^(8UFP_=_ZVV7XG^#-$)QR#F_TF[R1TQCFOC?\ 8H_Y.M^"
M7_8YR^G3^PM9SU]O\YQ7[,?M;_"W2?@S_P $[_$'PVT9A/:>%-'^'VEO<E%B
M^WZB?B-X3NM9U/RHU"QOJ6I7%_J#Q(-D4ER\4?R**_&S]B;'_#5?P3SC;_PF
MDV[/_8M:YUSVQUS_ (UW8"NL3EF88M6=\PQUWK=MX-)W_'3K:Y\_X@9!4R+Q
M%\'\IQ<K8K)LMR++[[?\QR6NO1KYVON?27_!3']H/Q=XV^-'B#X06>J7-CX
M^'HTS3[G1;>XDMD\0>)M0TFRUNYU#41YOEW,=C%?VVGZ>DL3&T^SWMU;2JFH
MW*-YS^S#^P-\1/VD?"EQXZM?%6A>!O"C:C?:5I-SJ.FZAK5_JD^F"1+F6#3X
M+C38;>SMKP"S>Y?40YN8+F%+25K:1ZZ;_@I9\&O$W@']H'7_ (@S6=Y-X)^)
MHTK5-.USR9)+*VU^QT2QTC4="O+[;Y=O>N-'?4K&U?;]KL+AEL_/:QNA:XG[
M+'[?'CO]FOPI+X$7P?IOCKPBFIWNJZ;:7FJ3>'M2T2;5$E>ZAM]0@T[58I[*
MYU$I?M;RZ=O%Q<7\XO$^T^5&L.ZL,GPSRK_>[KOM9;::;63MJ[WN>5F=3)ZO
MC%G3\7EF']E?VACO[-TQNC>-7U&WU/\ Y@_J>J>M][/4O?M/_P#!/WQ!^S/\
M-S\0]4^*&E>+[-_$&E:,FE67A6?1)?.U&*^F:<W%QKVK*R1I9$>4(E(W[M^$
M(7F/^";V?^&P/A7LSG[-XRQN_P"Q'\0=>WW>F??'&:L_M _M@?&_]K;1]2\*
M1>"K73?!/AA'\9:[H?A73M5UZ\TZRT 2B?6_$.OSHB0:180WP2>Y&G:/90>9
M&;PSRO;R#Y9^$_Q,\2_"'QYX=^)7A1H3K7A:\DO[.*]@FDL[F.>SNM/O;>YA
MM+J"1X+JRO+B"55FCEVR[D:*98W3MP]/,L5E&)PN)UQ6,ULU?MOLK:W?=[::
MGSF<8_@;(O$OAS->#,NS#!Y!@LPP.8:O&_\ "A]1QJ^O?4?KGEH]E=.W0_=O
M_@KLV?@5X*&<@_%S0F7CC:?!/CT>U?F[_P $Q]W_  USX)VY_P"17\;Y]-W]
MCR?>S_P+&??'>OL+_@H+XL\4>/?V+?@/XW\::=I>D^)?%'C3P?K^K:;H[3MI
M^GS:OX \;W\%K:F__P!-81P74*$R_O=ZR&0G)W?D/\'_ (J^,?@EXYL?B/X%
MFL8-:T&*^@5]2TU[[2Y;/4K62TN(=3ACEBE:"YBE=&,-Q:3HK;H+B&79,O'E
M%*K/A[$831.V-6U];1M=>3W3\_0_0_%+/\+A/'7ASBNJT\KP2R_,):?[?]1]
MW&/3?\=]-MO[.><$@J%P22!@GCOG\:_FT_X*O>)[/6OVD-&TFR=))?"_PYTO
M3M18LN8KW4=5UO5Q;%<MD+I^H:?<JS*,_:MJ\J^WN9O^"NWQ>DT.:S7X7^";
M?7I++RDU@ZOK4FG_ &KR_P#CX.@ "?R_,.?LQU\, 0YG*GR*_-'5M5\>?&;X
MC7>I7,>J^-/B+X]UV.1;73K"2XU/6M6O&1(X;6SL(CY-I:P(EM%%!%%9Z=86
MZK'':65J$M_.X;R3$X#&_6\7M%;WLK:=?EH]--SZ3QZ\9N'N/N&<-PEP<LQS
MG%XW,L LQM@<9IJG]1M;5MO>ZVMLS]C_ /@CII=RFA_'C7'5I;2]U7P/HD:D
M%=MQHNGZ[>7B@D;2?)U[3WX)!$@ .58+[C\>?^"8?P=^+.L:GXM\%ZUJ7PJ\
M2ZY<75_J2:-9V^J^$[[4;QVN[K4#X>FET^:WN[^\D>:[;3]:M+-3-++'I_VB
M1KAO3?@!\ =>_9Q_9*\0^"K>]:S^(^I^$_&'B?6]2T>6%IK;QWK6@3Q646EW
ML,$)EDT-K?2-*LM0"@3?V9!>G'GL5_)?X9?\%3_VCO"6GP6/B:#PE\3;>WAA
M@>ZUO3I=#UUGBB?:\VI^'/L^FIO.P22W&AW4O!.7#)&G%?,L?F>88O+L0[W5
MW_,M%YIVTM\MD?=+_4+@'PXX*X-\3LF^N_7<NQV8W6 >._L_'?7?KF-;^I?[
M9@W_ +8U=:Z*^URG\;?^":7QL^$7AO6_&6CZYX?^)'AWP_I]UJ.L6NE17&D^
M(K;3[,R37>H#2+OSK6YAM+!'N)8;#5;J]=(Y%BLI2-H^2?V?_BWXF^"7Q8\)
M>/?"U_=VPL]6T^VUZQC9Q!X@\+W%[:2:SH>HQI*@G@O[6(K;22B9+&_BL]2A
MA>\M;39]O?%C_@J/\5OB7X*\1>"])^'WA;P++XCTV^T*^U^#6=1\0:G;:;JE
MJ]E=OIMO<:=H]IIU\MO),D5S<)JT(9UE6"&2%#)\>?LP? SQ/\<OBUX4\)Z%
MI]U+HMEJ]AJ'C'55C*V&B>%[68W.HSW-TS1Q0WU]:6L]CHUO)(K76JS008\E
M+F:W^IP=3$_4,3_;=[66K6NRU=NJ=]>V[V/YBXGP_#-7CC)5X+8C,?K:S# ;
MK&V_M!8V*P/U#Z[W:;Q>MK6L]6C^PD"->.OKCZ8/Z?4U\;?%W]AC]GWXW>,;
MCQ[X^\-ZQJ/B:[TZRTJYO-,\3>(-#M[FVTW @$UIIFIVD/GJBK%]I\OSF@CC
M@\[RHXU7[ FEDCAW(Q4Y![>A/\Z99RO=(_FG)!'(R#P?K_3N:_+,-+%X:]6E
MB&G>SWOIJOS[Z=C_ %(SKAS*.),K<,^RS!9Q@&D_J>.@YP^RELG_ %I<^8_@
M7^R!\$?V>]5UG6OAOH&H:;J6MVL6GWMQJ.N:OKCFR@N/M7DP#4[^Z-NCW 0N
M(MGG""V$H=;:(I]3E2$W 9Z\#V'3I_\ 6_G5><"!1Y8 SCD\D=N.PX]J>97,
M(YY(SG\_P[#M67UBKBZBJ5&F[\NO5V3Z>CU3[::!E.2Y;PYEZAE>78++\"K?
M['@H.$-7%;R6]WUO^C^?/C%^RY\#OCYJ&DZS\5O!T?BG4?#UA?:=H\KZQKVD
MFUM]0N+.XO(D;0]4TV3,T^GVVXO(R[8@O"LU2_!O]E[X'_ :^UG5/A3X13PK
M>^(;2QL-7D&LZ_JWVR#3I;V>SW/KNJ:I(C0MJ%T%,3H,2A2& 4#Z(;H?H?Y?
MYZ\4R'J_/^=N>V*OV^+4/8>WE['1<J?^'R2V:6O_  #'_53A[^TO[<_L?+5F
MF_\ :/U2']H-::/%\W/TVM9'R%X]_8>_9K^)GB[5_'OCCX=0ZUXJUZ>WNM6U
M,^(_%ED;N:RLK/3[8&ST[7K:Q41V=C;0*5MU8I%^\W,6W>Q?"?X/_#_X(>$Q
MX.^&GAY?#OAV.^O]1CTT7^IZD5O=3NFNKF<76K7VH7K*\TDDFV6ZD"ER$(7:
M$]?4YC9B!G&<=NI]_P"O/>JSY8C)(R>W'8]^OZU7ML75C]6J5W*@K>[JNS7D
M]%U^2[/+^$^'\'CL5FV6Y/EN$S3%)\^91P=-XQ--?;O9^J:V5T]$L?5M&T_7
M=,NM(UG3[35=+O[>>UOK#4+:WO+*[M[A2L]O=6EP)(IX)$+(\4J2HZ,492K$
M-\"^*O\ @F)^REXHU6;4(M \1>$9)W1YK7P?XEU'3-,/E! BP:5J']J:38K@
M$>7I]K9H Q50J94?HQY:Y!ZD>N/\*@D8A21C/T'H32PV,Q=-+ZG7EA;67NI-
MWTU7I;Y^FACQ#P;P]Q)2PW]O9/EF<?5&N7Z]A(3O?1;?>[]?Q^*?A;_P3Z_9
MD^$VJ6NO:/X%37O$-C(DMEK'BJ]NO$4MI.D31)<VEC<,FB6=XBR,8[VUTNTN
MHB=T4\9+L8?C%_P3\_9R^,OB"[\9Z[X;U'0?$]_(\NJZSX1U6;1)M6>7R=\^
MIV4D5[HUY>2>2OFZC-IAU*5&,<EZ80%/V_#([QY9B3M'ZKFFO(\: J>?4@=R
M>/TKH6/Q[FJ[KOV]OCOI9V\K[=NIXZ\/N"?['^H/AW+?[)W^H_5*7+VWYK7O
M?R/D[PQ^Q?\  7PO\(]8^!L'AB^U3P!XCUFWU_Q!I^JZWJ;W>K:O:7FG7UK<
M76I:?>:?>PF*32--"+I[VD*)9PQQQ1H65L?PA^P;^RMX'\1Z3XR\.?#&VLM>
MT&^MM5TB]N-?\7:K'I]_9RI-:W$=MJFO7UF'MIHXY(V,#,DJ)*G[Y$=?M' X
MXZ=*>,88X]/\\8_R!Z5E]=QW_03+WFNGE'K?32VJ_37N_P!1>$$\N_XQ[*O^
M$=+^S?\ 9*?_  G[/_8W]C5;M7^3:*4:2.FY4\H'K$>PZ9QQ^GJ?;'@GQE_9
MP^#?QW&EGXJ>"[3Q-_84L\ND7;ZCJ^D7]HMX8FNK?^T-"O\ 3;U[6=K6V9[6
M6=[=G@C?RPP;?[]:H%W$$G@CDY[']:8Z@Q[3R!T!^H-82Q-3"UE4I>[MM=.S
M2EO?T6^NM]SV*^5Y=GV6XG"X_+<#C<)B5[V7YC3>,P-HM;PFDWUZ=O*WS+\)
M?V0/V?\ X)>*)O&/PT\"KX:\0S:1=Z)-J2:]XCU,OIU[=6=Y<6Y@UC6-1MD#
MW&GVD@>.*.7,"_O1R!]1'[N "0<XQGC^I.?Z]JJ3L;8*(<+NZD\GCIC/2D2>
M7R,[N0V >_\ ^OD]/QK6HJ]5JK4K.5VHV6FO5VLUTZM_@5EF3Y;D65<N79;@
M<OP*2_V/!4W"'1KXK+Y=W<U6< XZ^O;'Z5EWMI;7\$]M<PP7%K/&T4T,Z)-%
M-$PVS130OE61E)4JX964X.01G2<#KWS_ $_^M1'W_#^M<QZ-2E"<))I:?Y/?
MOMWNM]S^<7]O;]@VZ^$5SJ7QA^$.GS7?PNNI9;[Q5X9LX#)-X!E.Z6;4+""%
M>/!6-TEW:Q )X: ::+.@;DT'\J5^\(]G[P_\LOZ_Y/X5_;G>VMM<6$MK<V\-
MS:W \F:WN(UEADC8.2K1N"IZ=P<9/?&/RL^#'[(7P0\*_M@_$N]T[P[<36O@
MK3/ OB[P=H5[<02:#X8UWQ;=^.(+V[TK3X+2WVIII\)VEQH%O=374&C7=]>W
M%I&LEKH1T;]!R3B/$T<%7I8M/%K"VE%R=KIN_P"B;]-S^"O&3Z/&5XCBG(<S
MR&O@LGP7%>/^HXS 1I5)1P6/T?U[ N,&E?7W9.+7GN</^P)^P,O@_P#LGXV_
M&S22?%NRWU#P/X'U& $^$V!$\&M:Y;W";AXF#K%/864R+)X;=4O+V,>)!!;^
M'/V=BPB!$>(*.!W'3'<;N/;OF@1(( H4 <CCCC(Z8Z?S],5&O[E0$Z9[C/K_
M )_'Z8^)S#,L1F>+52M+=Z*[T2LM+=][._K8_KC@/@7(O#K(\/D>48?_ )=>
MWS',G;Z[C\2[)U)RM:VG\R=NFNFG12+T'T'\J6N0_03Q'QS\"_A1\3[BPO\
MX@_#[PAXRU+38)[2SNO$&A:?J\MG;W,J33PVK7T,OV?>T:;VB$;,% /&<Y]M
M^S?\"+#PSJG@^U^$WP^A\+:K??VAJ?AZ'PKHRZ1>ZG]E%DVIW-@+(6TFI&V
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MX<6.MZ5>VNI:7J=GX5T6UO\ 3KZRNA>V=[8WD-M%/:7-K=9EBEMWB=&!V.%
M4_1[J.#WSZGT/^?2H]Y+D$*<#()'/;N,5%*=:E3=.G5E&*U?6^L=]>OK?L[K
M7U<;D66YE7PN,Q>79;CJ^%6D\;@X3OI%75G+6^Z?_ '(24D4D2^N!C.<^H']
M#[\UX-\1_P!FSX'?%B1[KX@?#'P=XEU+84&JWFDP)K(79Y>R/6[46VK0QA!C
M9!>HO)&W!(;W4J"<G/TSQ_GZ4DW[D#R^,D?KNK&&(G0M[-V=WMHM+6VW_P"&
M[$8G+,MSR'U/'Y9@L=AU:\<QA+%W=DUI.R[]?O/C.T_X)Z?L?V[K)!\%?#S2
MH0X,^H>)+R+.3@^5=:Y,@.,'./0 G!Q]*^!_AGX&^&VEC1/ WA/P]X7TF, )
M9^'M(LM(@)!)#S)91P)-(,D>8R;L'EFPNWT$ ;1[CG\JJR.T>0F!CV'J1_GW
MKH5?%UE:I7<KZ]=[)]]K):6_)'G83A?AG(9?6<!DV7X"M;XL#E^$IZ66FL8]
MUUO>]FNO'^+_  =X7^(F@77AGQEX>TSQ-X=U!K9K_0]<L;;4-,NS97<5Y:?:
MK.[C>WN1#=VT%S&DL4B++%$ZJ60-7FGAK]E[]G[P=KFG^)?#?P@^'NAZYI%R
M;O3-3TCPGHNG7UA<L,&:RN;*VADM7'3,3+R<#CFO=-.FEF5FD=F( QDG SG.
M/2M!_NGDCZ?E4REBJ"=*%>R5DWJ[WMN]+VTULFON9ZN,X?RG$8W"2QN79=B<
M?A5>&,E@X<W397\MG^!R_B;PAX:\9Z/=^'_%6@Z3K^C:A$T-[I6L6%KJFGW<
M+#F.XL[Q);>0>@>-P"%8;CC;\IO_ ,$^OV0KB9KN3X*>'TF9D<10WGB*TMP$
M "_Z%9:U#8QX !"Q6T: <"-0"@^S(6+AB0,[2<@8]1].E.FYWY[XS^.*<:N+
MHW5/$-/2SU5MGI9^6^^YYN+X=X:SVMAYYADN7X[_ +#<OPE1[+7X6M+Z+R^[
MR_P)\(OAA\+]%;P]X"\#>&?"FBW04W%GH6B6>FQWC+DB74&@BC-U,"3^_NO,
MF(VCS-H4#PS4?V#?V2M7UBXUBZ^"/@Z&\FE,T\5FE_I>G,S,9#LTC2K[3])C
MS(Q<[+( L=QRS%A]AP\(X' _^MFHD=BQ4G@8QZ]">O\ /UJH5L72<O9UW'EL
MGJ]6TG?2WEZ&6*X8X6KQPF&QN29?BJ.&2>6QEE^$_P!BV^"\7UVMT;ZGF_BS
MX0_#+Q[HMCX=\;^!_#/BO1-*GBN=)TG7M(L]4LK&\@@FMH+R""^BN(X)Q;W,
MUL)@GF!)95! =PW.^'?V;_@1X/DU&;PQ\(_ &AMJ^E_V'J[Z;X5T:S_M+1?M
M$5V=+U 06<8O-/\ M4$$_P!CN!-:;XT?R3M%>Y@Y0Y[ C\A[4Y0 !CT'^?;\
M*S]KBN3E^L2O\VMDNZ[=NO0ZYY'DF*FL;4RS .OJ^;^S\+T25MNMU?;31'QC
MK/[ O[)6LW<E]<?!'PC;W$C[V326U/P[:ABJH2+#P[?Z58Y 0$N8"YZ%B%5:
M]=^''[/_ ,'/@X)9?AE\,_"7A>]DC6&?4M.TJV_MF>!%54BNM;N$FU:\155=
MJW5Y,HPI"?(JCW!QA?Q^OKZU2DQ*,2 . ,<YS^A%:+$8VM2Y*N(;5TM+M6=E
MMIV_3O?@H<*<*99BUB,)D>78'&/59A@LOPE/&7=EK4<5UOU+)3]V1-L]>.?K
MR/\ /TR /G?QQ^RS^SQ\1KE[[QC\)O .K:DY8R:N/#]M9ZW(9 P8-KE@EKJV
M"&(.V['&1]TE3]'$ ]1G_/\ ]:LZ^FECX1V4!0<*<<].WU_05GAUB:<K4Z[B
M[7V:VMO9[+I^AZ]?)<MS^D\)C\NR[&T$DW',<'#&7V7VVEKIT77<^-;?_@GO
M^R#:RF:W^"WA]Y CJ?M.H>([Z JZE6S9:AK-S9-D$DB2WD1N0T94[6^I?!?P
M\\&_#W1TT+P1X6T+PKI$9S'IWA_3+/2[",X"DI:644-NIQC.V-06Y."QKML#
M&,<51N)7B.$P.1VR>@/7_(J_;XK$^[4KR>J=W=OMJW?[K:=-D>5A.&N&>'I?
67L!DN7X&OTE@<!A:5MMM(V>JUN?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
